Safety Of Cisplatin Chemotherapy Research Articles

An Observational Study on Tolerability and Safety of Cisplatin Chemotherapy in Various Cancer

Abstract: Aim: To find out the safety and tolerability of cisplatin either given as individual therapy or in combination with other anticancer drugs or with radiotherapy. Materials and Methods: A prospective observational study was conducted in the oncology department (inpatient) of tertiary care hospital. The data was collected from the in-patient department after considering inclusion and exclusion criteria for a period of 6 months. Safety was analyzed using EORTC scales and Tolerability was assessed by collecting the laboratory data every week of the therapy. Statistical tools like Chi-square test were applied to the data by using SPSS software. Results: A total of 107 cancer patients, female patients predominated over males. Most common age group were under of 51-60 years. All the patients in our study were treated with cisplatin in combination with radiotherapy than monotherapy or in combination with other anticancer drugs. Higher incidence of tongue cancer cases were reported followed by less number of anal cancer cases. The quality of life and the functioning ability of cancer patients are calculated via EORTC scale. The QOL is highest in esophageal cancer patients and the lowest in cervical cancer patients. The social functioning of the subjects is very good in every cancer whereas the physical functioning is decreased in anal and buccal cancer patients. The cisplatin is given in the combination with radiotherapy for a total of 6 weeks. Every week after the therapy, the blood samples were collected and the toxicities are checked. Nausea and vomiting, fatigue, loss of appetite, insomnia are the side effects seen during the therapy. Few cases of Hematological toxicities like reduction in Hb count, PCV, lymphocyte count and increase in Neutrophil count were seen. By this, we can say that cisplatin is well tolerated and is safe in the chemotherapy with minimal side effects. Conclusion: Cisplatin is well tolerated in adults who are diagnosed with various cancers with minimal side effects which were controlled with supportive therapy. Whereas no serious ADRs reported in the study and no recurrence of the disease was observed. Thus, cisplatin is beneficial in the treatment of various cancers as it is safe and well tolerated. Keywords: Cisplatin, ADR, Re-occurrence, Hb, PCV, Safety and tolerability, Various cancers, EORTC scale.

Cisplatin chemotherapy in the treatment of BRCA1-positive metastatic breast cancer (MBC)

1099 Background: Preclinical data suggest that women with BRCA1 related breast cancers may be particularly sensitive to chemotherapeutic agents that cause DNA damage such as cisplatin chemotherapy. This study was conducted to assess the efficacy and safety of cisplatin chemotherapy in patients with BRCA1 positive MBC. Methods: This was a multicenter, open label, single arm study of cisplatin 75 mg/m2 given intravenously every three weeks until disease progression or toxicity. The primary objective was to assess antitumour activity of cisplatin, as measured by clinical benefit response (CR, PR, or SD ≥ 6 months). Eligible patients had locally recurrent or MBC, had 0–2 prior chemotherapy regimens in the metastatic setting, and had received prior therapy with an anthracycline. Patients were restaged every eight weeks. The study protocol was approved by the institutional review boards of participating institutions. Results: A total of 15 patients were enrolled. Mean age was 48.1 years (range: 32 to 70). ECOG performance status scores were 0 (6 pts), 1 (5 pts), 2 (4 pts). All patients had a confirmed BRCA1 mutation (7 with C61G mutation, 7 with 5382 insC, 1 with 4153delA). Five patients (33%) were ER or PR + and none were HER-2+. Prior history of MBC chemotherapy included 1 regimen (4 pts) and 2 regimens (7 pts). Seven (46%) and 4 (26%) patients had complete and partial responses by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, for an overall response rate of 72%. Median duration of response has not yet been reached. In general, cisplatin was well tolerated. Neutropenia was the commonest toxicity with 33% grade 2 (6,7% and 0%, grades 3 and 4 neutropenia). No patients developed febrile neutropenia. Conclusions: Significant activity and favorable toxicity profile provides a basis for considering cisplatin for further evaluation in phase III trials for women with BRCA1 positive MBC. No significant financial relationships to disclose.